ABSI Stock Absci Corporation
BUY US · NasdaqGSAI-enabled drug discovery creates asymmetric upside around partnerships and clinical milestones.
Future value: $20.00 (+111.64%) · 6-12 months
Signal breakdown
- ▸KeyCorp maintained Overweight and raised its target.
- ▸Above 50-day MA (+1.17%)
- ▸Above 200-day MA — long-term uptrend
- ▸~112% upside to price target
Is ABSI a buy right now?
Trend: ABSI is trading above the 50-day average (+1.18%), RSI 50 — neutral momentum, with a 3-month return of +32.54%.
Valuation & quality: Absci Corporation trades on forward P/E -14.0, price-to-book 6.59; fundamentals show net margin 0.0%, return on equity -57.7%, revenue growth -46.4% year on year.
Analyst consensus: 10 analysts have a mean 12-month price target of $14.90 (+57.7% vs the last close; range $10.00 – $20.00), consensus rating “strong buy”.
Our screen: BUY (score 3) — AI-enabled drug discovery creates asymmetric upside around partnerships and clinical milestones.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +9.50% | +65.70% | +35.80% | +71.70% | -32.90% | +16.20% | +19.10% | -12.30% |
Fundamentals
Analyst price target
Technical signals
About Absci Corporation
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.
Sector: Healthcare · Industry: Biotechnology · United States · 140 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.